Related Experiment Videos
The structural basis for LRRK2's activation and autoinhibition
Amalia Villagran Suarez1, Kathryn S Hatch1, Tatyana Bodrug1
1Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Cell
|August 10, 2026
Summary
Leucine-rich repeat kinase 2 (LRRK2) mutations drive Parkinson's disease (PD). GTP binding activates LRRK2, while GDP binding inhibits it, offering new therapeutic strategies for PD by controlling LRRK2 states.
Area of Science:
- Biochemistry
- Structural Biology
- Neuroscience
Background:
- Mutations in leucine-rich repeat kinase 2 (LRRK2) are a significant cause of autosomal-dominant Parkinson's disease (PD).
- Elevated LRRK2 kinase activity is implicated in idiopathic PD, highlighting LRRK2 as a key therapeutic target.
- LRRK2 is a large enzyme comprising Ras-like GTPase (ROC) and kinase domains.
Purpose of the Study:
- To elucidate the regulatory mechanism of LRRK2 kinase activity.
- To investigate how Parkinson's disease-associated mutations affect LRRK2 function.
- To provide a structural basis for LRRK2 regulation and therapeutic targeting.
Main Methods:
- Cryo-electron microscopy (cryo-EM) for high-resolution structural analysis.
- Biochemical reconstitution assays to study enzyme activity.
- Cell-based assays to validate findings in a biological context.
Main Results:
- The ROC GTPase domain controls LRRK2's switch between autoinhibited and active states.
- GTP binding promotes LRRK2 activation, whereas GDP binding induces autoinhibition.
- Common PD mutations (G2019S, R1441C/G/H) activate LRRK2 via distinct structural pathways, indicating genotype-specific dysregulation.
Conclusions:
- A unified framework for LRRK2 regulation based on GTPase activity is established.
- Stabilizing the GDP-bound state offers a potential therapeutic strategy to inhibit LRRK2 in PD.
- Modulating LRRK2 activity, particularly the GTP-bound state, may have context-specific roles, e.g., in lung physiology.